InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,461.34
(
-0.22%
)
US TECH 100
19,207.20
(
-0.27%
)
Dow Jones
39,136.46
(
0.00%
)
Brent Oil
84.41
(
-0.71%
)
Bitcoin
63,729.88
(
-1.68%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Thursday, 07/18/2013 8:40:45 PM

Thursday, July 18, 2013 8:40:45 PM

Post# of 80490
More hope for Pona in NSCLC...

Like the sound of FGFR3 inhibitors being for used for "other" resistant pathways (mentions EGFR) in lung cancer.

"These results identify an FGF9-FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways."

http://cancerres.aacrjournals.org/content/early/2013/07/18/0008-5472.CAN-13-0495.abstract
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up